Directorate Change
Verici Dx Plc announced that Non-Executive Director James McCullough has resigned from the Board with immediate effect to focus on his CEO role at Renalytix plc, and the company has commenced its search for a replacement.
Select text to share a quote on X · sign in to keep highlights & notes in your VRCI notes
Verici Dx Plc, (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that James McCullough, Non-Executive Director, has resigned from the Board with immediate effect to focus on his role as CEO of Renalytix plc.
The Company has begun its search for a replacement Non-Executive Director to join the Board and will provide an update in due course.
Sara Barrington, Chief Executive Officer, said: "It has been a pleasure to work alongside James for the last five years and I would like to thank James for his expertise, advice and contribution to the Company. I wish James every success and all the best for the future."
| Verici Dx plc | www.vericidx.com |
| Sara Barrington, CEO | Via Walbrook PR |
| Singer Capital Markets (Nominated adviser, Joint Broker) | Tel: +44 (0)20 7496 3000 |
| Phil Davies | |
| Oberon Capital (Joint Broker) | Tel: +44 (0)20 3179 0500 |
| Mike Seabrook / Adam Pollock | |
| Walbrook PR (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or vericidx@walbrookpr.com |
| Alice Woodings / Rachel Broad | Mob: +44 (0)7407 804 654 / +44 (0)7747 515 393 |
Verici Dx
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.